

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



RemeGen Co., Ltd.*

榮昌生物製藥（煙台）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 9995)

POLL RESULTS OF THE 2024 FIRST EXTRAORDINARY GENERAL MEETING

Reference is made to the circular (the “**Circular**”) of RemeGen Co., Ltd.* 榮昌生物製藥(煙台)股份有限公司 (the “**Company**”) incorporating, amongst others, the notice of 2024 first extraordinary general meeting (the “**EGM**”) dated May 30, 2024. Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Circular.

ATTENDANCE AT THE EGM

The Board is pleased to announce that the EGM was held at Room 6134, Phase III Building of the Company at 58 Middle Beijing Road, Yantai Development Zone, Yantai Area of Shandong Pilot Free Trade Zone, the PRC on Monday, June 17, 2024 at 2:00 p.m.

The attendance of the EGM was as follows:

Class of Shares	Number of Shares in issue (and entitling holders to attend and vote for or against resolutions)	Number of Shares present (in person or by proxy)	Approximate % of Shares present (in person or by Proxy)
A Shares	354,750,844	205,270,755	37.7106
H Shares	189,581,239	33,399,312	6.1358
Total	544,332,083	238,670,067	43.8464

To the best knowledge, information and belief of the Company: (1) there were no Shares entitling the holder to attend and abstain from voting in favour of the resolutions proposed at the EGM as set out in Rule 13.40 of the Listing Rules; (2) no Shareholder was required under the Listing Rules to abstain from voting on the resolutions proposed at the EGM; and (3) no party has stated any intention in the Circular to vote against or to abstain from voting on any of the resolutions proposed at the EGM.

The EGM was convened by the Board. Save for non-executive Director Dr. Su Xiaodi, all other Directors attended the EGM.

POLL RESULTS OF THE EGM

The poll results of the EGM were as follows:

Special resolutions		Number of votes and percentage of the total voting shares at the EGM			Passed by Shareholders
		For	Against	Abstain	
1.	To consider and approve the proposal in relation to the fulfilment of the conditions for the Proposed Issuance by the Company.	234,900,207 98.4205%	3,759,860 1.5753%	10,000 0.0042%	Yes
2.	To consider and approve the proposal in relation to the Plan of the Proposed Issuance:				
	(1) Class and nominal value of Shares to be issued;	234,900,207 98.4205%	3,759,860 1.5753%	10,000 0.0042%	Yes
	(2) Method and time of issuance;	234,900,207 98.4205%	3,759,860 1.5753%	10,000 0.0042%	Yes
	(3) Target subscribers and subscription method;	234,900,207 98.4205%	3,759,860 1.5753%	10,000 0.0042%	Yes
	(4) Number of Shares to be issued;	234,900,207 98.4205%	3,759,860 1.5753%	10,000 0.0042%	Yes
	(5) Price Determination Date, issue price and pricing principles;	234,900,207 98.4205%	3,759,860 1.5753%	10,000 0.0042%	Yes
	(6) Lock-up period;	234,900,207 98.4205%	3,759,860 1.5753%	10,000 0.0042%	Yes
	(7) Amount and use of proceeds;	234,900,207 98.4205%	3,759,860 1.5753%	10,000 0.0042%	Yes
	(8) Listing venue of the Shares;	234,900,207 98.4205%	3,759,860 1.5753%	10,000 0.0042%	Yes
	(9) Distribution arrangement of accumulated profits; and	234,900,207 98.4205%	3,759,860 1.5753%	10,000 0.0042%	Yes
	(10) Validity period of the resolutions in relation to the Proposed Issuance.	234,900,207 98.4205%	3,759,860 1.5753%	10,000 0.0042%	Yes
3.	To consider and approve the Proposal for the Proposed Issuance.	234,900,207 98.4205%	3,759,860 1.5753%	10,000 0.0042%	Yes
4.	To consider and approve the proposal in relation to the Demonstration and Analysis Report regarding the Plan of the Proposed Issuance.	234,889,707 98.4161%	3,770,360 1.5797%	10,000 0.0042%	Yes
5.	To consider and approve the proposal in relation to the Feasibility Report on the Use of Proceeds from the Proposed Issuance.	234,889,707 98.4161%	3,770,360 1.5797%	10,000 0.0042%	Yes

Special resolutions		Number of votes and percentage of the total voting shares at the EGM			Passed by Shareholders
		For	Against	Abstain	
6.	To consider and approve the proposal in relation to the Report on the Use of Proceeds Previously Raised.	238,637,428 99.9863%	22,639 0.0095%	10,000 0.0042%	Yes
7.	To consider and approve the proposal in relation to the dilution of immediate return resulting from the Proposed Issuance and remedial measures adopted by the Company and undertakings by relevant subjects.	234,889,707 98.4161%	3,770,360 1.5797%	10,000 0.0042%	Yes
8.	To consider and approve the proposal in relation to the Dividend Distribution Plan for the Shareholders for the Next Three Years (2024 to 2026).	238,637,428 99.9863%	22,639 0.0095%	10,000 0.0042%	Yes
9.	To consider and approve the proposal for authorizing the Board and persons authorized by the Board to deal with all matters in relation to the Proposed Issuance at the general meeting.	234,889,707 98.4161%	3,770,360 1.5797%	10,000 0.0042%	Yes

As not less than two-thirds of the votes casted in favour of the special resolutions numbered 1 to 9 above, the resolutions were duly passed.

The H share registrar of the Company, Computershare Hong Kong Investor Services Limited, acted as the scrutineer for the vote-taking at the EGM. Two representatives of the Shareholders, two lawyers of King & Wood Mallesons and one Supervisor of the Company participated in the scrutiny of the poll results.

By order of the Board
RemeGen Co., Ltd.*
Mr. Wang Weidong
Chairman and executive Director

Yantai, the PRC
June 17, 2024

As at the date of this announcement, the Board comprises Mr. Wang Weidong, Dr. Fang Jianmin, Dr. He Ruyi and Mr. Lin Jian as the executive Directors, Dr. Wang Liqiang and Dr. Su Xiaodi as the non-executive Directors, and Mr. Hao Xianjing, Dr. Ma Lan and Mr. Chen Yunjin as the independent non-executive Directors.

* For identification purposes only